Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

The Word Brain 2015Free PDF | Print | Web
A short guide to fast language learning

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 133 articles:
HTML format
Text format



Single Articles


    August 2016
  1. RIBERO S, Marra E, Tomasini CF, Fierro MT, et al
    Confocal microscopy and dermoscopy for the monitoring of BRAF inhibitor therapy of melanoma skin metastases.
    Br J Dermatol. 2016 Aug 12. doi: 10.1111/bjd.14951.
    PubMed     Text format     Abstract available


  2. RIBERO S, Osella-Abate S, Reyes-Garcia D, Grulich A, et al
    Gender effects on naevi body distribution and melanoma risk in two melanoma case control studies at different latitudes.
    Br J Dermatol. 2016 Aug 1. doi: 10.1111/bjd.14915.
    PubMed     Text format     Abstract available


    July 2016
  3. MANGAS C, Potrony M, Mainetti C, Bianchi E, et al
    Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
    Br J Dermatol. 2016 Jul 30. doi: 10.1111/bjd.14897.
    PubMed     Text format     Abstract available


  4. WILLIS CM, Britton LE, Swindells MA, Jones EM, et al
    Invasive melanoma in-vivo can be distinguished from basal cell carcinoma, benign naevi and healthy skin by canine olfaction: a proof of principle study of differential volatile organic compound emission.
    Br J Dermatol. 2016 Jul 25. doi: 10.1111/bjd.14887.
    PubMed     Text format     Abstract available


  5. GRANT WB
    Increased risk of non-cutaneous malignancy after diagnosis of non-melanoma skin cancer may be due to sun avoidance.
    Br J Dermatol. 2016 Jul 15. doi: 10.1111/bjd.14862.
    PubMed     Text format     Abstract available


  6. PARDO LM, van der Leest RJ, de Vries E, Soerjomataram I, et al
    Comparing survival of patients with single or multiple primary melanoma in The Netherlands: 1994-2009.
    Br J Dermatol. 2016 Jul 5. doi: 10.1111/bjd.14846.
    PubMed     Text format     Abstract available


  7. KIRBY LC, Banerjee A, Augustine T, Douglas JF, et al
    An ethical dilemma: malignant melanoma in a 51-year-old patient awaiting simultaneous kidney and pancreas transplantation for type 1 diabetes.
    Br J Dermatol. 2016;175:172-4.
    PubMed     Text format     Abstract available


    June 2016
  8. SHITARA D, Tell-Marti G, Badenas C, Enokihara MM, et al
    Discrepant mutational status between naevi and melanomas in naevus-associated melanomas: about mutation-specific immunohistochemistry: reply from the authors.
    Br J Dermatol. 2016 Jun 16. doi: 10.1111/bjd.14613.
    PubMed     Text format    


  9. TEULINGS HE, Lommerts JE, Wolkerstorfer A, Nieuweboer-Krobotova L, et al
    Vitiligo-like depigmentations as first sign of melanoma; a retrospective case series from a tertiary vitiligo centre.
    Br J Dermatol. 2016 Jun 7. doi: 10.1111/bjd.14790.
    PubMed     Text format     Abstract available


  10. STEFANAKI I, Stratigos AJ
    Inherited susceptibility to melanoma: insights from a high-risk Austrian cohort.
    Br J Dermatol. 2016;174:1188-90.
    PubMed     Text format    


    May 2016
  11. RANSOHOFF KJ, Stefanick ML, Li S, Kurian AW, et al
    Association of non-melanoma skin cancer with second non-cutaneous malignancy in the Women's Health Initiative.
    Br J Dermatol. 2016 May 26. doi: 10.1111/bjd.14766.
    PubMed     Text format     Abstract available


  12. TRAUTMANN F, Meier F, Seidler A, Schmitt J, et al
    Effects of the German skin cancer screening program on melanoma incidence and indicators of disease severity.
    Br J Dermatol. 2016 May 20. doi: 10.1111/bjd.14758.
    PubMed     Text format     Abstract available


  13. THURNEYSEN S, Cheng PF, Nagel HW, Kunz M, et al
    An exploratory study investigating the metabolic activity and local cytokine profile in melanoma patients treated with pazopanib and paclitaxel.
    Br J Dermatol. 2016 May 11. doi: 10.1111/bjd.14727.
    PubMed     Text format     Abstract available


  14. MCCONNELL AT, Ellis R, Pathy B, Plummer R, et al
    The prognostic significance and impact of the CXCR4/CXCR7/CXCL12 axis in primary cutaneous melanoma.
    Br J Dermatol. 2016 May 11. doi: 10.1111/bjd.14720.
    PubMed     Text format     Abstract available


  15. PATHRIA G, Garg B, Garg K, Wagner C, et al
    Dual JNK-Cyclin D1 and ERK-c-JUN Disjunction in Human Melanoma.
    Br J Dermatol. 2016 May 5. doi: 10.1111/bjd.14713.
    PubMed     Text format     Abstract available


  16. PIANA S, Moscarella E, Longo C
    Image Gallery: Brain? no, melanoma.
    Br J Dermatol. 2016;174:e41.
    PubMed     Text format    


  17. SCHOFIELD JK, Robinson R, Reeken S, Jackson R, et al
    National Institute for Health and Care Excellence melanoma guidelines: good news for patients but challenging to implement.
    Br J Dermatol. 2016;174:949-50.
    PubMed     Text format    


    April 2016
  18. MENIN C, Bojnik E, Del Bianco P, Elefanti L, et al
    Differences in telomere length between sporadic and familial cutaneous melanoma.
    Br J Dermatol. 2016 Apr 7. doi: 10.1111/bjd.14652.
    PubMed     Text format     Abstract available


  19. GALLAIS SEREZAL I, Beaussant Y, Rochigneux P, Tournigand C, et al
    End-of-life care for hospitalised patients with metastatic melanoma in France: a nationwide, register-based study.
    Br J Dermatol. 2016 Apr 1. doi: 10.1111/bjd.14631.
    PubMed     Text format     Abstract available


  20. HORSHAM C, J Loescher L, Whiteman DC, Soyer HP, et al
    Consumer acceptance of patient-performed mobile teledermoscopy for the early detection of melanoma.
    Br J Dermatol. 2016 Apr 1. doi: 10.1111/bjd.14630.
    PubMed     Text format     Abstract available


  21. OREGAARD JS, Jarjis RD, Venzo A, Jemec B, et al
    Cover Image: Unique presentation of a subungual malignant melanoma in situ.
    Br J Dermatol. 2016;174:935.
    PubMed     Text format    


  22. SULLIVAN RJ
    Serum lactate dehydrogenase is a more useful biomarker of prognosis than serum S100B in patients with BRAF-mutant melanoma.
    Br J Dermatol. 2016;174:716-7.
    PubMed     Text format    


  23. BAADE PD
    Quantifying the mortality burden for skin cancers other than melanoma.
    Br J Dermatol. 2016;174:713-4.
    PubMed     Text format    


    March 2016
  24. UGUEN A
    Discrepant mutational status between naevi and melanomas in naevus-associated melanomas: about mutation-specific immunohistochemistry.
    Br J Dermatol. 2016 Mar 31. doi: 10.1111/bjd.14603.
    PubMed     Text format     Abstract available


  25. PARKINS G, Brown E, Gupta G
    Radiological imaging in all stage III melanoma- current practice in the United Kingdom.
    Br J Dermatol. 2016 Mar 15. doi: 10.1111/bjd.14551.
    PubMed     Text format     Abstract available


    February 2016
  26. CHAPPUIS P, Duru G, Marchal O, Girier P, et al
    Dermoscopy: A useful tool for general practitioners in melanoma screening: A nationwide survey.
    Br J Dermatol. 2016 Feb 23. doi: 10.1111/bjd.14495.
    PubMed     Text format     Abstract available


  27. STASER K, Chen D, Solus J, Rosman IS, et al
    Extensive tumoral melanosis associated with ipilimumab-treated melanoma.
    Br J Dermatol. 2016 Feb 15. doi: 10.1111/bjd.14474.
    PubMed     Text format     Abstract available


  28. SARGEN MR, Merrill SL, Chu EY, Nathanson KL, et al
    CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic nevi, and internal malignancies: A case series and review of the literature.
    Br J Dermatol. 2016 Feb 15. doi: 10.1111/bjd.14485.
    PubMed     Text format     Abstract available


  29. NALDI L, Cazzaniga S
    Prediction of high total naevus count to estimate melanoma risk. We need more, don't we?
    Br J Dermatol. 2016;174:261-2.
    PubMed     Text format    


    January 2016
  30. MULLER C, Wendt J, Rauscher S, Burgstaller-Muehlbacher S, et al
    Characterization of high risk melanoma patients in Austria.
    Br J Dermatol. 2016 Jan 22. doi: 10.1111/bjd.14407.
    PubMed     Text format     Abstract available


  31. MATTER-WALSTRA K, Braun R, Kolb C, Ademi Z, et al
    Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors.
    Br J Dermatol. 2016 Jan 20. doi: 10.1111/bjd.14279.
    PubMed     Text format    


  32. CHMIELOWSKI B
    Prognostic and predictive biomarkers for the benefit of immunotherapy in patients with metastatic melanoma.
    Br J Dermatol. 2016;174:20.
    PubMed     Text format    


    December 2015
  33. FERNANDEZ-VEGA I, Santos-Juanes J, Fresno-Forcelledo MF
    Primary amelanotic rhabdoid melanoma of the forehead.
    Br J Dermatol. 2015 Dec 29. doi: 10.1111/bjd.14382.
    PubMed     Text format     Abstract available


  34. ROACH RE, Plasmeijer EI, van Doorn R, Bergman W, et al
    The value of clinical characteristics for the diagnosis of melanoma in patients presenting at a pigmented lesion clinic.
    Br J Dermatol. 2015 Dec 26. doi: 10.1111/bjd.14375.
    PubMed     Text format     Abstract available


  35. EISEMANN N, Jansen L, Castro FA, Chen T, et al
    Survival from non-melanoma skin cancer in Germany.
    Br J Dermatol. 2015 Dec 16. doi: 10.1111/bjd.14352.
    PubMed     Text format     Abstract available


  36. FRAUCHIGER AL, Mangana J, Rechsteiner M, Moch H, et al
    Prognostic relevance of LDH and serum S-100 levels in Stage IV melanoma with known BRAF mutation status.
    Br J Dermatol. 2015 Dec 13. doi: 10.1111/bjd.14347.
    PubMed     Text format     Abstract available


  37. CURL PK
    Navigating uncertainty: a valuable cost-effectiveness analysis in the rapidly changing field of metastatic melanoma treatment.
    Br J Dermatol. 2015;173:1365-6.
    PubMed     Text format    


    November 2015
  38. TSCHANDL P, Berghoff AS, Preusser M, Pammer J, et al
    Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and nevi in vivo.
    Br J Dermatol. 2015 Nov 28. doi: 10.1111/bjd.14323.
    PubMed     Text format     Abstract available


  39. MONCRIEFF M, Fadhil M, Garrioch J
    Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases (LIMMs) of the skin. The 5-Year Norwich experience.
    Br J Dermatol. 2015 Nov 24. doi: 10.1111/bjd.14314.
    PubMed     Text format     Abstract available


  40. GUIDA S, Pellacani G, Cesinaro AM, Moscarella E, et al
    Spitz naevi and melanomas with similar dermoscopic pattern: can confocal microscopy differentiate?
    Br J Dermatol. 2015 Nov 11. doi: 10.1111/bjd.14286.
    PubMed     Text format     Abstract available


  41. SEBARATNAM DF, Anforth R, Fernandez-Penas P
    Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma.
    Br J Dermatol. 2015 Nov 2. doi: 10.1111/bjd.14264.
    PubMed     Text format     Abstract available


    October 2015
  42. RIBERO S, Zugna D, Osella-Abate S, Glass D, et al
    Prediction of high naevus count in a healthy UK population to estimate melanoma risk.
    Br J Dermatol. 2015 Oct 19. doi: 10.1111/bjd.14216.
    PubMed     Text format     Abstract available


    September 2015
  43. MOSER J, Moshammer R, Koglbauer G, Kitzwogerer M, et al
    Sentinel-node biopsy in melanoma: A single center experience with 216 consecutive patients.
    Br J Dermatol. 2015 Sep 24. doi: 10.1111/bjd.14189.
    PubMed     Text format     Abstract available


  44. ZARAGOZA J, Caille A, Beneton N, Bens G, et al
    Neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.
    Br J Dermatol. 2015 Sep 6. doi: 10.1111/bjd.14155.
    PubMed     Text format     Abstract available


  45. MATTER-WALSTRA K, Braun R, Kolb C, Ademi Z, et al
    A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-positive melanoma in the Swiss setting.
    Br J Dermatol. 2015 Sep 2. doi: 10.1111/bjd.14152.
    PubMed     Text format     Abstract available


  46. KRAFT S, Tsao H
    Melanoma-associated naevi: precursors or coincidence?
    Br J Dermatol. 2015;173:633-4.
    PubMed     Text format    


  47. SCHOFIELD JK
    Sentinel lymph node biopsy: in support of equity of access, informed shared decision making and patient choice.
    Br J Dermatol. 2015;173:863-4.
    PubMed     Text format    


    August 2015
  48. MONCRIEFF M, Garioch J
    MSLT-I: it's all about the lymph nodes....
    Br J Dermatol. 2015;173:626-7.
    PubMed     Text format    


  49. MCGREGOR JM, Sasieni P
    MSLT-I: it's all about the lymph nodes...: reply from the authors.
    Br J Dermatol. 2015;173:627-8.
    PubMed     Text format    


    July 2015
  50. BENATI E, Argenziano G, Kyrgidis A, Moscarella E, et al
    Melanoma and naevi with globular pattern: Confocal microscopy as an aid for diagnostic differentiation.
    Br J Dermatol. 2015 Jul 25. doi: 10.1111/bjd.14049.
    PubMed     Text format     Abstract available


  51. LALLAS A, Kyrgidis A, Koga H, Moscarella E, et al
    The BRAAFF checklist: a new dermoscopic algorithm for diagnosing acral melanoma.
    Br J Dermatol. 2015 Jul 25. doi: 10.1111/bjd.14045.
    PubMed     Text format     Abstract available


  52. LI Z, Wang Z, Yu Y, Zhang H, et al
    Smoking is Inversely Related to Cutaneous Malignant Melanoma -Says Results from a Meta-analysis.
    Br J Dermatol. 2015 Jul 2. doi: 10.1111/bjd.13998.
    PubMed     Text format     Abstract available


  53. DAVIES MA
    BRAF in early stage melanoma: rationale for testing and treatment?
    Br J Dermatol. 2015;173:9-10.
    PubMed     Text format    


  54. GOHARA M
    Skin cancer: an African perspective.
    Br J Dermatol. 2015;173 Suppl 2:17-21.
    PubMed     Text format     Abstract available


    June 2015
  55. SINHA R, Larkin J, Gore M, Fearfield L, et al
    Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Br J Dermatol. 2015 Jun 24. doi: 10.1111/bjd.13958.
    PubMed     Text format     Abstract available


  56. FINNANE A, Soyer HP
    Smartphone diagnosis of skin cancer: there's not yet an app for that.
    Br J Dermatol. 2015;172:1474-5.
    PubMed     Text format    


  57. WU S
    Do mutations in BRCA1/BRCA2 confer a higher risk of skin cancer?
    Br J Dermatol. 2015;172:1473.
    PubMed     Text format    


  58. GUMASTE PV, Penn LA, Cymerman RM, Kirchhoff T, et al
    Skin cancer risk in BRCA1/2 mutation carriers.
    Br J Dermatol. 2015;172:1498-506.
    PubMed     Text format     Abstract available


  59. VIGARIOS E, Lamant L, Delord JP, Fricain JC, et al
    Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.
    Br J Dermatol. 2015;172:1680-2.
    PubMed     Text format    


    May 2015
  60. THOMAS L
    Dermoscopy for melanoma: don't forget to take a photo.
    Br J Dermatol. 2015;172:1182-3.
    PubMed     Text format    


    April 2015
  61. JAFARI SM, Hunger RE, Shafighi M
    Lack of strong evidence in depth of thick melanoma excision.
    Br J Dermatol. 2015 Apr 27. doi: 10.1111/bjd.13871.
    PubMed     Text format     Abstract available


  62. PIZZICHETTA MA, Kittler H, Stanganelli I, Bono R, et al
    Pigmented nodular melanoma: The predictive value of dermoscopic features using a multivariate analysis.
    Br J Dermatol. 2015 Apr 27. doi: 10.1111/bjd.13861.
    PubMed     Text format     Abstract available


  63. SHITARAA D, Tell-Marti G, Badenas C, Enokihara MM, et al
    Mutational status of nevus associated-melanomas.
    Br J Dermatol. 2015 Apr 9. doi: 10.1111/bjd.13829.
    PubMed     Text format     Abstract available


  64. MARCHIORI BAKOS R
    Dermoscopy of naevoid melanoma.
    Br J Dermatol. 2015;172:848-9.
    PubMed     Text format    


  65. IDORN LW
    New insights into the association of socioeconomic status with cutaneous malignant melanoma.
    Br J Dermatol. 2015;172:846-7.
    PubMed     Text format    


  66. OAKLEY AM
    Mobile teledermatology is here to stay.
    Br J Dermatol. 2015;172:856-7.
    PubMed     Text format    


  67. MANAHAN MN, Soyer HP, Loescher LJ, Horsham C, et al
    A pilot trial of mobile, patient-performed teledermoscopy.
    Br J Dermatol. 2015;172:1072-80.
    PubMed     Text format     Abstract available


  68. DEBARBIEUX S, Gaspar R, Depaepe L, Dalle S, et al
    Intraoperative diagnosis of nonpigmented nail tumours with ex vivo fluorescence confocal microscopy: 10 cases.
    Br J Dermatol. 2015;172:1037-44.
    PubMed     Text format     Abstract available


    March 2015
  69. MAR VJ, Liu W, Devitt B, Wong SQ, et al
    The role of BRAF mutations in primary melanoma growth rate and survival.
    Br J Dermatol. 2015 Mar 5. doi: 10.1111/bjd.13756.
    PubMed     Text format     Abstract available


  70. FARIES MB, Cochran AJ, Elashoff RM, Thompson JF, et al
    Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: Response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal
    Br J Dermatol. 2015;172:571-3.
    PubMed     Text format     Abstract available


  71. SLADDEN M, Zagarella S, Popescu C, Bigby M, et al
    No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report.
    Br J Dermatol. 2015;172:566-71.
    PubMed     Text format     Abstract available


  72. ATTARD NR
    Head and neck melanoma: pattern of sun exposure and histological subtypes.
    Br J Dermatol. 2015;172:560-1.
    PubMed     Text format    


  73. SWETTER SM
    Thinner melanomas and improved survival among men in Sweden from 1997 to 2011.
    Br J Dermatol. 2015;172:559-60.
    PubMed     Text format    


  74. MCGREGOR JM, Sasieni P
    Sentinel node biopsy in cutaneous melanoma: time for consensus to better inform patient choice.
    Br J Dermatol. 2015;172:552-4.
    PubMed     Text format    


    February 2015
  75. CARRERA C
    High-risk melanoma patients: can unnecessary naevi biopsies be avoided?
    Br J Dermatol. 2015;172:313-5.
    PubMed     Text format    


    January 2015
  76. LONGO C, Moscarella E, Argenziano G, Lallas A, et al
    Reflectance confocal microscopy in the diagnosis of solitary pink skin tumors: Review of Diagnostic Clues.
    Br J Dermatol. 2015 Jan 30. doi: 10.1111/bjd.13689.
    PubMed     Text format     Abstract available


  77. KASSIANOS AP, Emery JD, Murchie P, Walter FM, et al
    Smartphone applications for melanoma detection by community, patient and generalist clinician users: a review.
    Br J Dermatol. 2015 Jan 20. doi: 10.1111/bjd.13665.
    PubMed     Text format     Abstract available


  78. JEUDY G, Dalac-Rat S, Bonniaud B, Hervieu A, et al
    Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.
    Br J Dermatol. 2015;172:1454-5.
    PubMed     Text format    


  79. RICHTIG E, Arzberger E, Hofmann-Wellenhof R, Fink-Puches R, et al
    Assessment of changes in lentigo maligna during radiotherapy by in-vivo reflectance confocal microscopy: a pilot study.
    Br J Dermatol. 2015;172:81-7.
    PubMed     Text format     Abstract available


    December 2014
  80. LIVINGSTONE E, Eigentler TK, Windemuth-Kieselbach C, Hauschild A, et al
    Actual practice of melanoma follow-up and treatment in Germany: Results of a prospective, longitudinal cohort study.
    Br J Dermatol. 2014 Dec 15. doi: 10.1111/bjd.13612.
    PubMed     Text format     Abstract available


  81. MORTON RL
    Essential inputs for studies of cost-effectiveness analysis in melanoma.
    Br J Dermatol. 2014;171:1294-5.
    PubMed     Text format    


  82. NALDI L
    Melanoma excision: how deep must we go?
    Br J Dermatol. 2014;171:1291-2.
    PubMed     Text format    


  83. BERMUDEZ Y
    Ultraviolet involvement in melanocyte transformation to melanoma.
    Br J Dermatol. 2014;171:1289.
    PubMed     Text format    


    November 2014
  84. GONZALEZ-ALVAREZ T, Carrera C, Bennassar A, Vilalta A, et al
    Dermoscopy structures predictors of sentinel lymph node positivity in cutaneous melanoma.
    Br J Dermatol. 2014 Nov 21. doi: 10.1111/bjd.13552.
    PubMed     Text format     Abstract available


  85. HUNGER RE, Seyed Jafari SM, Angermeier S, Shafighi M, et al
    Excision of fascia in melanoma thicker than 2 mm: no evidence for improved clinical outcome.
    Br J Dermatol. 2014 Nov 13. doi: 10.1111/bjd.13478.
    PubMed     Text format     Abstract available


  86. LONGO C, Piana S, Marghoob A, Cavicchini S, et al
    Morphologic features of nevoid melanoma Results of a Multicenter Study of the International Dermoscopy Society.
    Br J Dermatol. 2014 Nov 12. doi: 10.1111/bjd.13524.
    PubMed     Text format     Abstract available


  87. GARCIA-CASADO Z, Traves V, Banuls J, Niveiro M, et al
    BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
    Br J Dermatol. 2014 Nov 10. doi: 10.1111/bjd.13521.
    PubMed     Text format     Abstract available


  88. KITTLER H
    B-RAF, naevi and melanoma: a complex relationship.
    Br J Dermatol. 2014;171:931-932.
    PubMed     Text format    


    October 2014
  89. JIANG AJ, Rambhatla PV, Eide MJ
    A Systematic Review of Socioeconomic and Lifestyle Factors and Melanoma.
    Br J Dermatol. 2014 Oct 30. doi: 10.1111/bjd.13500.
    PubMed     Text format     Abstract available


  90. DABOUZ F, Barbe C, Lesage C, Le Clainche A, et al
    Clinical and histological features of head and neck melanoma: a population-based study in France.
    Br J Dermatol. 2014 Oct 21. doi: 10.1111/bjd.13489.
    PubMed     Text format     Abstract available


  91. MENIS D, Maronas-Jimenez L, Rodriguez-Peralto J, Martin-Llamas R, et al
    Two Spanish cases of Atypical Melanosis of the Foot, an early stage of Acral Lentiginous Melanoma in situ.
    Br J Dermatol. 2014 Oct 16. doi: 10.1111/bjd.13485.
    PubMed     Text format     Abstract available


  92. PONTI G, Manfredini M, Tomasi A, Pellacani G, et al
    Distinctive clinical and dermoscopic features of BRAFp.V600K mutated melanomas.
    Br J Dermatol. 2014 Oct 16. doi: 10.1111/bjd.13484.
    PubMed     Text format     Abstract available


  93. LYTH J, Eriksson H, Hansson J, Ingvar C, et al
    Trends in cutaneous malignant melanoma in Sweden 1997-2011: Thinner tumours and improved survival among men.
    Br J Dermatol. 2014 Oct 16. doi: 10.1111/bjd.13483.
    PubMed     Text format     Abstract available


  94. EVANS CL
    Peering under the skin: measuring melanoma depth with ultrasound and optical coherence tomography.
    Br J Dermatol. 2014;171:690-1.
    PubMed     Text format    


    September 2014
  95. WATTS CG, Dieng M, Morton RL, Mann GJ, et al
    Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review.
    Br J Dermatol. 2014 Sep 10. doi: 10.1111/bjd.13403.
    PubMed     Text format     Abstract available


    August 2014
  96. STANGANELLI I, Longo C, Mazzoni L, Magi S, et al
    Integration of reflectance confocal microscopy in sequential dermoscopy follow-up improves melanoma detection accuracy.
    Br J Dermatol. 2014 Aug 25. doi: 10.1111/bjd.13373.
    PubMed     Text format     Abstract available


  97. MOSCARELLA E, Al Jalbout S, Piana S, Argenziano G, et al
    The stars within the melanocytic garden: Unusual variants of Spitz nevi.
    Br J Dermatol. 2014 Aug 13. doi: 10.1111/bjd.13347.
    PubMed     Text format     Abstract available


  98. LAWRENCE CM, Rahim R, Charlton F, Husain A, et al
    Prospective study of formalin-fixed Mohs surgery and haematoxylin and eosin stains with control contralateral biopsies for lentigo maligna: 5-year follow-up results.
    Br J Dermatol. 2014;171:298-303.
    PubMed     Text format     Abstract available


    July 2014
  99. BERETTI F, Manni P, Longo C, Argenziano G, et al
    CD271 is expressed in melanoma with more aggressive behavior with correlation of characteristic morphology in in vivo reflectance confocal microscopy.
    Br J Dermatol. 2014 Jul 26. doi: 10.1111/bjd.13301.
    PubMed     Text format     Abstract available


  100. BRUGIERE C, Stefan A, Morice C, Cornet E, et al
    Vemurafenib skin phototoxicity is indirectly linked to UVA-MED decrease.
    Br J Dermatol. 2014 Jul 26. doi: 10.1111/bjd.13300.
    PubMed     Text format     Abstract available


  101. TROMME I, Devleesschauwer B, Beutels P, Richez P, et al
    Health related quality of life in melanoma patients expressed as utilities and disability weights.
    Br J Dermatol. 2014 Jul 12. doi: 10.1111/bjd.13262.
    PubMed     Text format     Abstract available


  102. ANFORTH R, Carlos G, Clements A, Kefford R, et al
    Cutaneous Adverse Events in Patients Treated with BRAF Inhibitor Based Therapies for Metastatic Melanoma for Longer than 52 Weeks.
    Br J Dermatol. 2014 Jul 9. doi: 10.1111/bjd.13200.
    PubMed     Text format     Abstract available


    June 2014
  103. SELLA T, Goren I, Shalev V, Shapira H, et al
    Incidence Trends of Keratinocytic Skin Cancers and Melanoma in Israel 2006-2011.
    Br J Dermatol. 2014 Jun 28. doi: 10.1111/bjd.13213.
    PubMed     Text format     Abstract available


  104. GAMBICHLER T, Kempka J, Kampilafkos P, Bechara FG, et al
    Clinicopathological characteristics of 270 lentigo maligna and lentigo maligna melanoma patients: data of a German Skin Cancer Center.
    Br J Dermatol. 2014 Jun 24. doi: 10.1111/bjd.13204.
    PubMed     Text format     Abstract available


  105. DE TROYA-MARTIN M, Rivas-Ruiz F, Blazquez-Sanchez N, Fernandez-Canedo I, et al
    Spanish version of the "skin cancer index". A questionnaire for measuring quality of life in patients with cervicofacial non-melanoma skin cancer.
    Br J Dermatol. 2014 Jun 7. doi: 10.1111/bjd.13173.
    PubMed     Text format     Abstract available


  106. ERIKSSON H, Frohm-Nilsson M, Jaras J, Kanter-Lewensohn L, et al
    Prognostic factors in localized invasive primary cutaneous malignant melanoma -results of a large population-based study.
    Br J Dermatol. 2014 Jun 7. doi: 10.1111/bjd.13171.
    PubMed     Text format     Abstract available


    May 2014
  107. PELLACANI G, Pepe P, Casari A, Longo C, et al
    Reflectance confocal microscopy as a second-level examination in skin oncology improves diagnostic accuracy and saves unnecessary excisions: a longitudinal prospective study.
    Br J Dermatol. 2014 May 29. doi: 10.1111/bjd.13148.
    PubMed     Text format     Abstract available


  108. MEYER N, Lauwers-Cances V, Lourari S, Laurent J, et al
    High frequency ultrasonography but not 930nm-optical coherence tomography reliably evaluates melanoma thickness in vivo: a prospective validation study.
    Br J Dermatol. 2014 May 23. doi: 10.1111/bjd.13129.
    PubMed     Text format     Abstract available


  109. MALVEHY J, Hauschild A, Curiel-Lewandrowski C, Mohr P, et al
    Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multi-centre, prospective and blinded clinical trial on efficacy and safety.
    Br J Dermatol. 2014 May 19. doi: 10.1111/bjd.13121.
    PubMed     Text format     Abstract available


  110. CHEVOLET I, Speeckaert R, Haspeslagh M, Neyns B, et al
    Peri-tumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
    Br J Dermatol. 2014 May 10. doi: 10.1111/bjd.13100.
    PubMed     Text format     Abstract available


    April 2014
  111. POZZOBON FC, Puig-Butille JA, Gonzalez-Alvarez T, Carrera C, et al
    Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
    Br J Dermatol. 2014 Apr 21. doi: 10.1111/bjd.13069.
    PubMed     Text format     Abstract available


  112. TALAGANIS JA, Biello K, Plaka M, Polydorou D, et al
    Demographic, behavioural and physician-related determinants of early melanoma detection in a low incidence population.
    Br J Dermatol. 2014 Apr 21. doi: 10.1111/bjd.13068.
    PubMed     Text format     Abstract available


  113. CHEVALIER V, Barbe C, Le Clainche A, Arnoult G, et al
    Comparison of Anatomic Locations of Cutaneous Melanoma in Men and Women: A Population-Based Study in France.
    Br J Dermatol. 2014 Apr 11. doi: 10.1111/bjd.13052.
    PubMed     Text format     Abstract available


  114. KOSE K, Cordova M, Duffy M, Flores ES, et al
    Video-Mosaicing of Reflectance Confocal Images For Examination of Extended Areas of Skin In Vivo.
    Br J Dermatol. 2014 Apr 10. doi: 10.1111/bjd.13050.
    PubMed     Text format     Abstract available


  115. HOLLESTEIN LM, Nijsten T
    The association between beta-blockers and melanoma survival: evidence of absence or absence of evidence?
    Br J Dermatol. 2014;170:764-5.
    PubMed     Text format    


    March 2014
  116. ROTA M, Negri E, Pelucchi C, La Vecchia C, et al
    Does alcohol consumption increase risk of cutaneous melanoma? Comments on a recent meta-analysis: reply from authors.
    Br J Dermatol. 2014 Mar 26. doi: 10.1111/bjd.12996.
    PubMed     Text format     Abstract available


  117. SUN V, Zhou WB, Majid S, Kashani-Sabet M, et al
    MicroRNA-mediated regulation of melanoma.
    Br J Dermatol. 2014 Mar 26. doi: 10.1111/bjd.12989.
    PubMed     Text format     Abstract available


  118. PASTUSHENKO I, Vermeulen PB, Van den Eynden GG, Rutten A, et al
    Mechanisms of tumour vascularisation in cutaneous malignant melanoma: clinical implications.
    Br J Dermatol. 2014 Mar 18. doi: 10.1111/bjd.12973.
    PubMed     Text format     Abstract available


  119. CHEN GC, Zhang Y
    Does alcohol consumption increase risk of cutaneous melanoma? Comments on a recent meta-analysis.
    Br J Dermatol. 2014 Mar 18. doi: 10.1111/bjd.12971.
    PubMed     Text format     Abstract available


  120. PICARD M, Pham Dang N, D'Incan M, Mansard S, et al
    Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.
    Br J Dermatol. 2014 Mar 6. doi: 10.1111/bjd.12939.
    PubMed     Text format     Abstract available


  121. DE WAAL AC, van Harten-Gerritsen AS, Aben KK, Kiemeney LA, et al
    Impact of mitotic activity on the pathological sub-staging of pT1 cutaneous melanoma.
    Br J Dermatol. 2014 Mar 5. doi: 10.1111/bjd.12898.
    PubMed     Text format     Abstract available


  122. MCCOURT C, Coleman HG, Murray LJ, Cantwell MM, et al
    Beta-blocker usage after malignant melanoma diagnosis and survival: A population-based nested case-control study.
    Br J Dermatol. 2014 Mar 5. doi: 10.1111/bjd.12894.
    PubMed     Text format     Abstract available


  123. FORSEA AM, Del Marmol V, Stratigos A, Geller AC, et al
    Melanoma Prognosis in Europe: Far from Equal.
    Br J Dermatol. 2014 Mar 3. doi: 10.1111/bjd.12923.
    PubMed     Text format     Abstract available


    February 2014
  124. ROTA M, Pasquali E, Bellocco R, Bagnardi V, et al
    Alcohol drinking and cutaneous melanoma risk - A systematic review and dose-risk meta-analysis.
    Br J Dermatol. 2014 Feb 3. doi: 10.1111/bjd.12856.
    PubMed     Text format     Abstract available


  125. SACHSE MM, Wagner G
    Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids.
    Br J Dermatol. 2014;170:475-7.
    PubMed     Text format    


    January 2014
  126. ECHEVERRIA B, Bulliard JL, Guillen C, Nagore E, et al
    Indicators for the total number of melanocytic naevi: an adjunct for screening campaigns. Observational study on 292 patients.
    Br J Dermatol. 2014;170:144-9.
    PubMed     Text format     Abstract available


  127. RIVERS JK
    Skin cancer: more than skin deep?
    Br J Dermatol. 2014;170:8.
    PubMed     Text format    


  128. FOGARTY GB, Hong A, Scolyer RA, Lin E, et al
    Radiotherapy for lentigo maligna: a literature review and recommendations for treatment.
    Br J Dermatol. 2014;170:52-8.
    PubMed     Text format     Abstract available


    August 2013
  129. DIFFEY B
    Sunbeds and young people: an easy target for legislation?
    Br J Dermatol. 2013;169:236-7.
    PubMed     Text format    


    July 2013
  130. ANFORTH R , Blumetti TC, Clements A, Kefford R, et al
    Systemic Retinoids for the Chemoprevention of Cutaneous Squamous Cell Carcinoma and Verrucal Keratosis in a Cohort of Patients on BRAF inhibitors.
    Br J Dermatol. 2013 Jul 20. doi: 10.1111/bjd.12519.
    PubMed     Text format     Abstract available


    June 2013
  131. BLACK N
    Patient-reported outcome measures in skin cancer.
    Br J Dermatol. 2013;168:1151.
    PubMed     Text format    


  132. DE VRIES K, Rellum R, Habets JM, Prens EP, et al
    A novel two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod.
    Br J Dermatol. 2013;168:1362-4.
    PubMed     Text format    


    March 2013
  133. GIBBONS E , Casanas I Comabella C, Fitzpatrick R
    A structured review of patient-reported outcome measures for patients with skin cancer, 2013.
    Br J Dermatol. 2013 Mar 14. doi: 10.1111/bjd.12310.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Pfizer Oncology.

Design: